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Abstract The majority of osteoporotic fractures happen in
individuals with BMD t-scores in the osteopenic range (−2,
5< t-score <−1). However, widespread use of anti-osteopo-
rotic medication in this group based on t-score alone is not
advisable because: 1) the number needed to treat is much
higher (NNT>100) than in patients with fractured and
t-score below −2,5 (NNT 10–20); 2)while specific osteo-
porosis treatments have demonstrated significant reductions
of the fracture risk in patients with t-score <−2, 5, the
efficacy in patients in the osteopenic range is less well
established. Therefore, an osteopenic t-score does not in
itself constitute a treatment imperative. Generally, osteope-
nia has to be associated with either low energy fracture(s)
or very high risk for future fracture as assessed with risk
calculators like FRAX to warrant specific osteoporosis
therapy. Vertebral fractures are now conveniently assessed
using lateral x-rays from DXA machines. In the vast
majority of cases antiresorptive treatments (mainly hor-
mone replacement therapy and SERMS in younger and
bisphosphonates or Denosumab in older women) are the
treatments of choice in this group of patients,—only rarely
is anabolic therapy indicated.
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1 Introduction
While pharmacological treatment of patients with prevalent
osteoporotic fractures is universally accepted, the treatment of
patients at increased risk of fracture due to low bone mass is
more controversial. Our ability to detect patients at increased
risk has improved significantly after the widespread availabil-
ity of Dual Energy X-ray Absorptiometry (DXA), which
provides a precise assessment of the amount of mineralized
bone in the skeleton. According to the WHO criteria for
assessment of DXA measurements, patients are considered
having low bone mass (osteopenic), when their BMD t-score
of the spine or hip lies between −1 and −2,5. Although fracture
risk increases with decreases in BMD, the vast majority of
osteoporotic fractures occur in osteopenic patients. This is due
to the fact that even though he risk of fracture is lower in the
osteopenia than in osteoporosis, the number of subjects at risk
is much higher in the osteopenic range due to the Gaussian
distribution of BMD values in the population (Fig. 1). In an
analysis of self reported fractures from the National
Osteoporosis Risk Assessment (NORA) study Siris et al.
[1] reported that 82% of postmenopausal women with
fractures had T scores better than −2.5. The study comprised
149 524 white postmenopausal women aged 50 to 104 years
(mean age, 64.5 years). New fractures were reported by
2,259 women, including 393 hip fractures; but only 6.4%
exhibited baseline T scores of −2.5 or less. Although fracture
rates were highest in women with a t-score <−2,5, only 18%
of the osteoporotic fractures and 26% of hip fractures
occurred in this group.
Osteoporosis leading to low energy fracture is often
compared to hypertension leading to stroke. We have
implemented widespread screening for high blood pressure
and the intervention threshold is low. Thus, from a general
health point of view, it would be beneficial to detect
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individuals at risk for low energy fracture and intervene
before the catastrophic event,—with all its potential
complications, happened. However, most clinicians are still
hesitant implying aggressive pharmacologic treatment
strategies in osteopenic patients. Several reasons for this
apprehension have been cited:
First, perceptions around disease severity are different
when comparing hypertension and osteoporosis. in the mind
of most clinicians. Osteoporotic fracture is considered a far
less severe event than stroke, although the increase in
mortality and morbidity after spine or hip fractures is
significant [2, 3].
Second, pharmaco-economic considerations also play a
role. A lot of these discussions have centered around estimates
of numbers needed to treat (NNT). While the most effective
antiresorptive treatment today have NNT values for preven-
tion of one fracture around 13–15 for spine fractures similar
numbers in osteopenia patients are 8–10 fold higher [4, 5]. As
shown in the analysis of Quandt et al. [4] the presence of a
prevalent fracture yields a NNT for subsequent fracture over
the next 5 years of 26, compared to 125 in patients without
fractures at entry into the study. The fact that most patients
with osteopenia are younger than the typical osteoporotic
women is also important. Riancho (1999) reported that NNT
for hip fractures ranged from 7 (for women aged 80 with a
bone mineral density [BMD] with Z-scores <−2) to 333 (for
women aged 50 with Z-scores between 0 and −1). Based on
these assumptions they calculated that therapy of 100 women
aged 80 years with a Z value <−2 for 3 years would prevent
14 hip fractures, 33 vertebral fractures and 8 wrist fractures.
Therapy of 100 women aged 50–55 years with a Z value
ranging from 0 to −1 would only prevent 1 hip fracture, 2
vertebral fractures and 2 wrist fractures [6]. Along the same
lines Lamy and Krieg reported the results of economic
analyses, which took into account the health care resources
needed to get these benefits. They found that at 50 years,
only calcium and vitamin D was cost-effective, whereas at
70 years, bisphosphonates and raloxifene were also cost-
effective [7].
Third, a few studies, in particular on bisphosphonates,
have hinted that clinical fractures were only significantly
reduced in patients with t-scores <−2,5 [8]. In the same
study, however, morphometric fractures were reduced even
in patients with a t-score >2,5.
Most guidelines for osteopenic patients therefore primarily
emphasize lifestyle changes like smoking cessation, nutrition-
al improvements, calcium and vitamin D supplementation,
exercise regimens etc. as primary interventions [9]. However,
as seen from the NORA data, a significant number of high-
risk osteopenic patients will still need pharmacologic
intervention in order to reduce their fracture risk significant-
ly. Identification of these individuals, however, demand
effective case finding strategies. This review will summarize
the current status of such strategies and the treatment options
available and end op proposing a treatment algorithm based
on this information.
1.1 Case finding strategies
While bone density remains one of the most valid and
reliable measures of fracture risk, a better delineation of
risk factors has led to renewed interest in absolute risk
(AR) models such as FRAX. New imaging approaches,
including lateral VFA, have been added to the diagnostic
armamentarium, and facilitate identification of fractures
earlier and with less radiation exposure to the patient.
This is important because of the severe consequences of
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women aged 50 to 104 years
(mean age, 64.5 years). Bone
mineral density (BMD) was
assessed by peripheral bone
densitometry at the heel, finger,
or forearm. Although fracture
rates were highest in women
with the lowest t-scores (open
bars), the largest absolute
number of fractures (black bars)
was seen in the osteopenic range
of t-score (−1 to −2,5). From
ref.1 with permission
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not only of the hip but also of the much more common
spine fractures.
1.1.1 Identification of osteopenic patients at increased risk
of fracture
BMD is related to bone strength and low BMD is a major
risk factor for fractures. However, most patients presenting
with a fracture do not have BMD based osteoporosis,
defined according to the World Health Organization (WHO)
definition as a T score of −2.5 or below. The most poignant
example is hip fracture, where only half the patients exhibit
t-scores below −2.5 [10]. In addition, and independent of
bone-related risks, extraskeletal risk factors such as falls
contribute to fracture risk and are present in the majority of
patients older than 50 years presenting with a clinical
fracture, and falls are the dominant event leading to forearm
and hip fracture [11].
1.1.2 Identification of patients with prevalent fractures
The primary risk factor for subsequent fracture is a
prevalent low energy fracture, irrespective of whether it is
clinically apparent or not. Thus, most guidelines for
treatment consider the presence of a low energy fracture
in an osteopenic patient a clear indication for specific
osteoporosis therapy [9, 12, 13]. A history of nonvertebral
fracture is associated with a doubling of the risk of a
subsequent fracture, and the subsequent fracture risk is even
quadrupled after a vertebral fracture. The re-fracture risk is,
however, not constant over time. It is highest (2–3X) in the
years immediately after a first fracture, followed by a
gradual waning later on [14]. Forty to 50% of all
subsequent fractures occur within 3 to 5 years after a first
fracture, and the presence of such fractures demands rapid
intervention with specific osteoporosis drugs to reduce the
risk of a subsequent fracture. Prevalent hip, spine and
several other nonvertebral fractures are all associated with
increased morbidity and mortality [15], which is higher
immediately after fracture than later on. Hip, vertebral, and
nonhip, nonvertebral fractures were each associated with
approximately one third of deaths. The major causes of
death were related to cardiovascular and respiratory
comorbidities [15].
Unfortunately subsequent follow up of fracture patients
after orthopedic fracture repair to identify patients in need
of specific osteoporosis treatment is still very limited. Most
studies show that only 10–15% of fracture patients treated
at orthopedic departments are offered a DXA evaluation,
and even less patients ar offered supplementation with
vitamin D and Ca or specific osteoporosis treatment.
Fortunately a lot of centres are recognizing this dilemma
and have established initiatives for post-fracture care (e.g.
fracture liaison service [16]. Such interventions have the
potential to reduce subsequent fractures, morbidity, mortality
and readmissions to hospital.
While hip and other nonvertebral fractures are clinically
obvious, the detection of vertebral fractures constitutes a
significant problem. Morphometric vertebral fractures are
the most frequent fractures in women and men older than
50 years [17] and their presence is a strong predictor of
future vertebral, nonvertebral, and hip fracture risk [18,
19]. Clinical vertebral fractures are characterized by back
pain lasting for 2–3 months, depending on fracture
severity, but they represent only a small subgroup of all
vertebral fractures. In recent large scale trials they
constitute less than 10% of all morphometric fractures
[20, 21]. Most morphometric vertebral fractures therefore
remain undiagnosed, which results in many patients
developing severe osteoporosis with multiple fractures
and chronic pain, before effective treatment is instituted.
Only when clinical suspicion, e.g. significant height loss,
increasing kyphosis, protruding abdomen, rib-iliac crest
distance of less than 2 cm, and acute or chronic back pain,
is raised, a spine x-ray is performed. But even when lateral
x-rays of the spine are available, vertebral fractures are
often missed [22, 23].
Thus, detection of prevalent fractures is very important
when making decisions on treatment in osteopenic women.
This has been further facilitated by accessory software for
DXA scanners yielding lateral x-rays of the spine, which
permit assessment of vertebral fracture status. This proce-
dure has been given many names: (vertebral morphometry,
lateral vertebral assessment (LVA), vertebral fracture assess-
ment (VFA) (Fig. 2). The images are usually of good
quality, albeit less detailed than conventional x-rays, and in
most cases a good evaluation of compression fractures in
the range Th4-L4 is possible. Advantages are: low radiation
dose, the availability of semiautomatic image analysis tools
to assist in measuring vertebral shapes of the individual
vertebrae, its plan-parallel projection, and its high negative
predictive value. The disadvantage is the inability to study
upper thoracic vertebrae, but only a minority of fractures
are found there. Indications for VFA according to the ISCD
[22] are shown in Table 1.
If pathology outside this region of interest (ROI) is
suspected, other imaging techniques will have to used. The
experience in most centres employing this methodology is,
however, that such referrals are needed in less than 10% of
cases. According to the International Society of Clinical
Densitometry (ISCD), additional x-ray imaging is needed in
cases of two or more mild (grade 1) deformities without
any moderate or severe (grade 2 or 3) deformities, when
lesions in vertebrae cannot be ascribed to benign causes, or
when vertebral deformities are found in a patient with a
known history of a relevant malignancy [22]. The method-
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Table 1 Indications for vertebral fracture assessment using x-ray absorptiometry after [22]
1. Postmenopausal women with low bone mass (osteopenia) by BMD criteria plus one of the following:
- Age of greater than or equal to 70 years.
- Historical height loss of greater than 4 cm.
- Prospective height loss of greater than 2 cm.
- Self-reported prior vertebral fracture (not previously documented).
- Two or more of the following:
Age of 60 to 69 years.
Self-reported prior nonvertebral fracture.
Historical height loss of 2 to 4 cm.
Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe chronic obstructive pulmonary
disease (COPD), seropositive rheumatoid arthritis, and Crohn disease).
2. Men with low bone mass (osteopenia) by BMD criteria plus one of the following:
- Age of 80 years or older.
- Historical height loss of greater than 6 cm.
- Prospective height loss of greater than 3 cm.
- Self-reported vertebral fracture (not previously documented).
- Two or more of the following:
Age of 70 to 79 years.
Self-reported prior nonvertebral fracture.
Historical height loss of 3 to 6 cm.
On pharmacological androgen deprivation therapy or following orchiectomy.
Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD, seropositive rheumatoid
arthritis, and Crohn disease).
3. Women or men on chronic glucocorticoid therapy (equivalent to 5 mg or more of prednisone daily for 3 months or longer).
4. Postmenopausal women or men with osteoporosis by bone density criteria (total hip, femoral neck, or lumbar spine T score of not more than
−2.5) if documentation of one or more vertebral fractures will alter clinical management.
A B CFig. 2 Spine imaging asobtained from VFA software on
DXA scanner. Normal spine (a);
young woman with vertebral
deformities (arrows) after post
partum osteoporosis (b); severe
osteoporosis in 68 year. old
woman with multiple moderate
and severe compression
fractures (c)
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ology also permits assessment of spondylosis and even
arteriosclerosis of the abdominal aorta can be evaluated.
The prevalence of previously unknown morphometric
vertebral fractures has been studied in various at-risk
populations. In a recent study of women and men
presenting with a nonvertebral fracture, one out of four
had a prevalent morphometric vertebral fracture on VFA
that was not recognized previously [24]. In another study,
the prevalence of morphometric vertebral fractures was
21% in postmenopausal women with osteopenia [25].
In patients with BMD-diagnosed osteoporosis, a baseline
VFA is not necessary for treatment decisions but is helpful
in detecting lack of treatment efficacy during follow-up.
Fractures occurring in L1-L4 will increase apparent BMD,
and may be difficult to see on the standard AP image
provided by a routine scan.
1.1.3 Identification of high risk individuals without fracture
history - the fracture risk assessment tool (FRAX)
As mentioned in the introduction, the vast majority of
osteoporotic fractures take place in osteopenic patients
without prevalent fractures. Many aspects of osteoporosis
and fracture risk are clinically recognizable (such as age,
gender, and body weight), even before a first fracture has
occurred. Relative risk estimates are, however, difficult to
apply in daily clinical practice since their clinical signifi-
cance depends on the prevalence of fractures in the general
population. In order to better delineate individuals at high
risk of osteoporotic fracture the WHO developed the
Fracture Risk Assessment (FRAX) tool (www.shef.ac.uk./
FRAX). It is an internet based clinical tool for calculation
of fracture risk in the individual patient based on assess-
ment of significant risk factors for osteoporotic fracture.
The FRAX algorithm is based on large-scale prospective
population-based studies which isolated the following risk
factors as significant determinants of fracture risk: age,
gender, body weight and body mass index, a history of
fracture, hip fracture in parents, current smoking, excessive
alcohol intake, rheumatoid arthritis, glucocorticoid use, and
other forms of secondary osteoporosis (Table 2) [13].
The National Osteoporosis Foundation (NOF) in the US
and the National Osteoporosis Society (NOS) in the UK have
integrated FRAX and BMD for case finding of individuals at
high risk for fracture and for treatment decisions in their new
guidelines. Treatment thresholds were put at 10-year fracture
risk estimates from the FRAX algorithm, at which fracture
prevention became cost-effective. Generally FRAX based ten
year risks of 20% or higher for all osteoporotic fractures and
3% or higher for hip fracture are considered reasonable
intervention thresholds [12, 13].
FRAX identifies patients at increased risk of osteopo-
rotic fracture based on some of the dominant risk factors,
but cannot be used in isolation. Several known determinant
of fracture risk are, however, not included in FRAX. The
algorithm does not take into account well known “dose
effects” like glucocorticoid dose. Incorporation of BMD
results is limited to results of BMD in the femoral neck.
However, total hip BMD is a more precise measure and can
be used interchangeably with femoral neck BMD in
women, but not in men. Vitamin D deficiency, a well
established risk factor for falls and hip fracture is not
included. The same holds for bone markers, which have
been shown to independently affect fracture risk. FRAX
may also underestimate fracture risk in individuals with
increased propensity for falls. More than 80% of women
and men presenting with a clinical fracture to the
emergency unit have one or more fall-related risks and
exhibit a fourfold increased risk of falls in the year leading
up to admission. In another study on 5- and 10-year
absolute risks for fractures in patients using glucocorticoids,
a history of falls had a greater impact on fracture risk than
any other evaluated risk [26]. Finally it is important to
remember that FRAX is only applicable in untreated
patients. It cannot be used as a helper in decision making
in patients, who already receive specific osteoporosis
treatment. A recent study from Switzerland used FRAX to
identify patient profiles with increased probability of
fracture beyond currently accepted reimbursement thresh-
olds for BMD and osteoporosis. The study found that in
particular age, BMI and parental history of fracture
increased the risk fo fracture substantially [27].
In patients with BMD-based osteoporosis or presenting
with a clinical fracture or both, diagnostic evaluation is
Table 2 Clinical risk factors and bone densitometry results that are




History of fracture after the age of 45 to 50 years
Parent with hip fracture
Current smoking
Alcohol intake of greater than 2 units per day
Glucocorticoid use
Rheumatoid arthritis
Other causes of secondary osteoporosis:
- Untreated hypogonadism in men and women, anorexia nervosa,
chemotherapy for breast and prostate cancer and hypopituitarism
- Inflammatory bowel disease and prolonged immobility (for
example, spinal cord injury, Parkinson disease, stroke, muscular
dystrophy, and ankylosing spondylitis)
- Organ transplantation
- Type I diabetes and thyroid disorders (for example, untreated
hyperthyroidism and overtreated hypothyroidism)
Femoral neck BMD.
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necessary to exclude secondary osteoporosis. Such evalua-
tions should include hematologic parameters (Hb, WBC),
serum 25-(OH)D3, calcium, creatinine, thyroid-stimulating
hormone, parathyroid hormone (PTH), serum/urine electro-
phoresis and testosterone (in me). According to the clinical
picture and suspicion, other serum measurements such as
plasma cortisol, tests for celiac disease and selected other
evaluations looking for secondary causes are indicated [28].
It is generally considered that secondary causes of
osteoporosis are more common in men than women.
Among secondary causes, hypogonadism resulting from
the treatment of breast cancer with aromatase inhibitors use
of androgen deprivation therapies in have become an
emerging clinical problem [29].
There is general consensus on the need for specific
osteoporosis treatment in patients with spine or hip
fractures and low BMD. For other nonvertebral fractures
different societies advocate different strategies. The NOS
recommends drug treatment in all postmenopausal women
with a history of any fragility fracture [12], while the NOF
advocates performing a dual-energy x-ray absorptiometry
(DXA) on patients after nonvertebral fractures to decide,
whether specific osteoporotic therapy is indicated. Drug
treatment should then be considered in patients having
osteoporosis and in patients with osteopenia when FRAX
indicates a 10-year fracture probability of at least 3% for
hip or at least 20% for major fractures [9].
1.2 Treatment options
1.2.1 Lifestyle changes
General changes in life style like smoking cessation, regular
exercise and optimization of nutirition should be imple-
mented in all osteopenic patients. Patient compliance with
these measures is, however, poor, and very few prospective
data on the anti-fracture efficacy of such measures exist..
Smoking has emerged as a significant risk factor for
fracture in many epidemiological studies [30–32], albeit
the influence of dose and duration is less well defined. The
same holds for exercise [33, 34], but exercise can slow
down bone loss after menopause and is important for
muscular strength and coordination in the elderly [32]. The
impact of poor nutrition on skeletal health is apparent in its
most extreme form in anorexia nervosa, where significant
improvement of skeletal mass is important without a
reversal of caloric intake in these young women [35, 36].
In recent years, vitamin D deficiency has emerged as a
very important risk factor for osteoporotic fracture, especially
at the hip. High turnover bone loss due to secondary
hyperparathyroidism due to vitamin D deficiency is consid-
ered a major pathogenetic factor in senile osteoporosis [37].
Vitamin D deficiency is endemic worldwide [38] and patients
with hip fracture generally have the lowest vitamin D levels
among all patient groups studied [39, 40]. Vitamin D
deficiency does not only cause weaker bones due to
osteomalacia, but also severe myopathy with loss of muscle
strength, selective loss of the rapid type-2 fibres, dyscoordi-
nation and consequently increased propensity for falls [41]. It
is therefore not surprising that meta-analyses indicate that
correction of vitamin D deficiency results in a decreased fall
and fracture risk [42, 43], but the effects depend on the dose
of vitamin D and the target population [44]. It is still a matter
of debate which doses of vitamin D3 or D2 supplementation
are necessary/optimal, taking into account baseline vitamin
D status and the desired serum levels to be achieved by
supplementation [31–33]. Daily intake of 400 IU/day is not
sufficient, while 800 IU/day reduce falls and fractures
significantly [42, 43]. In a recent controlled clinical trial
Bischoff-Ferrari et al. demonstrated that in a population of
post hip fracture patients maybe even higher doses are
warranted. In this study a dose of 2,000 IU/day of D3 was
superior to 800 IU/day in a cohort of 176 patients all
undergoing moderate physiotherapy. Over a 1 year period the
dose of 200 IU resulted in 25% less falls, 39% less
readmissions to hospital and a staggering 90% reduction in
all cause infections, when compared to 800 IU per day [45].
Several reviews have emphasized the need of addition of
calcium to vitamin D for fracture prevention and a dose of
1,000 to 1,200 mg/day was advocated [46]. Whether the
calcium dose can get too high is still a matter of debate, but
studies from one center published in 2008 reported that
supplements of 1,000 mg calcium/day on top of a baseline
intake of 800 mg/day increased the risk of vascular events
including myocardial infarction in healthy postmenopausal
women men [47, 48]. In this context, it is reassuring that,
when intake of vitamin D3 is sufficient, the need for
calcium intake is considered to be lower [49].
1.2.2 Prevention of falls and protection against fall trauma
Over 90% of hip fractures and all Colles fractures are caused
by falls, mostly in house. Vitamin D supplements improve
muscle function and decrease the risk of falls, as discussed
above. The role of physical exercise is still debated, but
exercise interventions together with other measures such as
removing loose carpets, reduce use of sleep medicine and
other tranquilizers, correct visual impairment etc. reduce the
risk and rate of falls in older people living in the community
[50], but no data that fall prevention decreases the risk of
fracture are yet available. The role of hip protectors remains
controversial. They seem to work in nursing homes [51, 52],
but less in community dwelling elderly, mainly due to
discomfort and practicality [53, 54].
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1.2.3 Pharmacotherapy
The last 2 decades have seen the emergence of an ever
growing list of effective and safe pharmacological agents for
the treatment of osteoporosis. These therapies for the
prevention and treatment of osteoporosis affect bone remod-
eling by either inhibiting bone resorption (antiresorptive or
anti-activation drugs) or enhancing bone formation (anabolic
regimens). Antiresorptive drugs do not lead to net accrual of
bone in the skeleton, despite the fact that BMD is increased.
Theymainly act by reducing bone turnover (therefore the term
anti-activation), thus reducing the impact of the negative
remodeling balance present in osteoporotics [55] and limiting
further deterioration of cancellous- and cortical bone
structure [56]. These drugs also reduce the remodeling space
and increase the degree by which bone matrix is mineralized,
which is behind the increase in BMD and add to the
antifracture efficacy of these agents. On average, these drugs
increase DXA BMD by 2–10%, and this increase is mainly
caused by reduced porosity of cortical and cancellous bone
combined with the increased incorporation of bone mineral
into bone matrix during low turnover. Antiresorptives
belonging to the bisphosphonate group are the most widely
used agents. These agents have shown significant efficacy in
randomized trials reducing event rates by up to 70% for
spine fractures, 40–50% for hip fractures and 20–25% for
nonvertebral fractures overall. Clinical painful spine fractures
show reductions of up to 85–90% [21, 57–59]. In hip
fracture patients, treatment with iv.bisphosphonatea further-
more has demonstrated a significant 28% reduction of all
cause mortality.
Anabolic drugs, of which only recombinant PTH are
currently available, on the other hand add net bone
mass to the skeleton and actually improve bone
structure and increase bone size from the osteoporotic
state [60, 61].
Despite the advances in pharmacotherapy the major-
ity of patients with osteopenia and osteoporosis are not
treated [50], and for patients who initiate therapy,
adherence to therapy is commonly below 50% at 1 to
2 years [51].
1.3 Antiresorptive (anti-activation) drugs
1.3.1 Estrogen
Estrogen receptors have been demonstrated on both
osteoblasts and osteoclasts [62, 63]. Estrogen replacement
therapy (ERT) or combined estrogen/progestin therapy
(HRT) reduces bone turnover by about 50% and improves
bone balance at each invidual BMU in postmenopausal
women [64]. The Women’s Health Initiative (WHI), a
randomized study comprising over 16,000 postmenopausal
women, demonstrated a significant 34% reduction of hip
fractures after treatment with combined conjugated equine
estrogen and [65] as well as estrogen alone in those women
who had undergone hysterectomy [66]. The study, however,
also found a nearly 30% increased risk of coronary heart
disease, 40% increased risk of stroke, increased risk of
thromboembolic events and 26–35% increased risk of
breast cancer. These results led to less enthusiasm for
long-term estrogen therapy world wide. The decision to
initiate ERT/HRT should be individualized and based on a
balanced assessment of risk and benefits by the physician
and patient. Current recommendations support restricting
the use of estrogen in most women to 5 years in the
perimenopausal period [67], with the aim mainly to reduce
hot flushes and other postmenopausal symptoms, and
regular mammography should be performed.
1.3.2 Selective estrogen receptor modulators
Selective estrogen receptor modulators (SERMs) are non-
steroidal synthetic agents, which exert estrogen-like prop-
erties on the bone and cardiovascular systems, but estrogen
antagonistic actions in the breast and, in some cases, the
endometrium. The first SERM developed both for breast
cancer prevention and for osteoporosis, raloxifene, is now
approved in many countries for the treatment of osteopo-
rosis. This drug was tested in the pivotal Multiple Out-
comes of Raloxifene Evaluation (MORE), a multicenter
study of over 7,700 postmenopausal women with at least
one vertebral fracture or osteoporosis on the basis of a T
score of −2.5 or below. In this study a dose of 60 mg/day
reduced vertebral fracture risk by 30% in patients with
prevalent fracture and 52% in patients without prevalent
fracture [68]. Similar to results obtained with another
SERM mainly used in oncology, tamoxifen, the risk of
invasive breast cancer was decreased by 72% during the
MORE study [69, 70]. In some women hot flashes and other
menopausal symptoms may recur on raloxifene. Similar to
estrogen, raloxifene, increases the risk of deep venous
thrombosis three-fold [68]. The STAR trial comparing
raloxifene to Tamoxifen found reported that Raloxifene
was as effective as tamoxifen in reducing the risk of
invasive breast cancer and carried a lower risk of
thromboembolic events and cataracts, but a non-statistically
significant higher risk of non-invasive breast cancer. The risk
of other cancers, fractures, ischemic heart disease, and stroke
was similar for both drugs [71].
Other SERMs, like Bazodoxifene and Lasofoxifene, are
currently under development.
Bazodoxifene decreases vertebral fracture risk to a
degree similar to that of raloxifene (approximately 40%
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over a 3-year period [89]) and, in a post hoc analysis,
reduced the risk of non-spine fractures in a subgroup of
patients with high risk for fractures based on FRAX [1].
Lasofoxifene was studied in the Postmenopausal Evalu-
ation And Risk reduction with Lasofoxifene (PEARL)
trial. The drug caused significant reductions compared
with placebo in vertebral and nonvertebral (but not hip)
fracture risk as well as in estrogen receptor positive
breast cancer with the 0.5 mg dose [72]. This is the only
SERM, to date showing significant reduction of non-
vertebral fractures as well as significant reductions in risk
of stroke, cholesterol levels and cardiovascular disease
[72, 73]. In this study, however, a small rise in overall
mortality was reported in the 0.25 mg dose but not with
the higher 0.5 mg dose.
1.3.3 Androgen replacement therapy in males
In hypogonadal males low testosterone levels result in a
high turnover state in bone leading to bone loss and
increased risk of fracture. The main driver of this turnover
increase is low circulating estrogen levels, just as in
postmenopausal women [74]. The low estrogen arises from
insufficient aromatase conversion from testosterone, either
due to low testosterone levels or insufficient aromatase
activity [75]. Testosterone replacement therapy in hypogo-
nadism will increase circulating estradiol levels and thereby
reduce bone turnover and increase BMD [76]. In hypo-
gonadism, usually defined as total testosterone levels below
8 nmol/l and hypogonadal symptoms [77], testosterone
replacement will lead to increases in bone mass similar to
those seen after ERT/HRT [77, 78], but randomized
controlled studies with fracture end points are still lacking.
Due to the fear of inducing prostate cancer clinicians have,
however, been quite reluctant to institute testosterone
replacement therapy. Recent data suggest, however, that
prostate cancers occurring in hypogonadal males have a
worse prognosis than cancers occurring in eugonadism,
[79]. Moreover, 16 population studies were unable to
demonstrate any relation between testosterone levels and
risk kfo prostate cancer [80]. Nevertheless, regular controls
of prostate specific antigen (PSA) and digitial rectal
exploration before and after institution of therapy is still
warranted.
1.3.4 Calcitonin
Both injectable and intranasal administration of calcitonin
results either stabilization of BMD or small increases in
spine BMD (1–3%) and reductions in bone turnover as
reflected in decreased levels of bone markers [81]. A 5-year
multicenter study of 1,255 postmenopausal women showed
a 36% reduction in vertebral fractures in the 200 IU, but not
in the two other dosage groups (100 and 400 IU). The study
also had a dropout rate of around 50% [82]. Calcitonin has
been shown to improve bone structure in the forearm [83].
Nasal calcitonin is generally well tolerated, with occasional
rhinitis. Headache, flushing, nausea, and diarrhoea have
been reported more commonly with subcutaneous, than
with intranasal calcitonin. Due to the absence of significant
reductions in hip- and nonvertebral fractures calcitonin is
considered a second- or third-line agent for osteoporosis
treatment in most countries.
1.3.5 Bisphosphonates
Bisphosphonates are potent inhibitors of bone resorption and
reduce the risk of osteoporotic fractures when administered
orally or by intravenous infusion [84]. They are simple
molecules with a P-C-P backbone and variations in the
structure of the amino side chains of these drugs determine
their pharmacological activity. The most common bisphosph-
onates licensed and used internationally are alendronate,
risedronate, ibandronate, and zoledronic acid. These drugs
are used in osteoporosis, Paget disease. In higher doses (10–
12 fold the doses used in osteoporosis) these drugs are used
for the treatment of advanced metastatic cancer with bone
involvement (e.g. multiple myeloma, breast and prostate
cancer) and hypercalcemia of malignancy..
All oral bisphosphonates are poorly absorbed, with
bioavailability of less than 1%. This limitation is overcome
by iv administration. After absorption the drugs are
primarily going to the skeleton or excreted via the kidneys.
This results in absence of detectable bisphosphonate in the
circulation 2–3 days after administration, while the drugs
exhibit a variable but generally long skeletal retention
(years to tens of years). Once adsorbed onto bone surfaces,
the mechanism of action is based on two actions: 1) tight
binding to hydroxyapatite crystals in bone; 2) inhibition of
important metabolic pathways in osteoclasts after incorpo-
ration during resorption of bisphosphonate coated bone.
The latter mechanism is either via accumulation of toxic
ATP analogues for non-nitrogen containing bisphospho-
nates or inhibition of a key enzyme in the mevalonate
pathway by nitrogen containing bisphosphonates impairing
cholesterol metabolism of the osteoclast and leading to
cytoskeletal alterations and premature osteoclast cell death
via apoptosis [84].
Histomorphometric analyses of bone biopsies obtained
from patients treated with bisphosphonates have revealed
dose dependent reduction in bone turnover, without any
adverse effects on osteoblastic function or matrix mineral-
ization [85, 86]. A few studies have also demonstrated
improved balance at the BMU-level [87].
Over prolonged administration, continued local inhibi-
tion of continuously deposited and recycled bisphospho-
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nates may partially account for a lack of rapid loss of BMD
gains, when these agents are discontinued [88], which is a
unique property, compared to other osteoporosis treatments.
The main side effect of oral bisphosphonates is gastro-
intestinal (GI) intolerance, [89]. Most reported GI symp-
toms have been non-ulcer dyspepsia, but in most clinical
trials, no significant differences between those treated with
bisphosphonates and those receiving placebo have been
demonstrable [89]. There have been rare reports of severe
esophagitis in patients taking oral bisphosphonates [90].
Recently two purported adverse effects to long term
bisphosphonate treatment have been reported and been
subject to significant scrutiny: 1) osteonecrosis of the jaw
(ONJ) 2) atypical femoral fractures. In relation to ONJ it is
important to distinguish between patients receiving
bisphosphonate therapy for advanced cancer with bone
metastases and patients receiving the drug for the treatment
of osteoporosis. In oncology only iv. Bisphosphonates are
used with doses exceeding the doses used in osteoporosis
by a factor of 10–12, and ONJ has been reported in an
estimated 1–2% of cancer patients receiving higher doses of
predominately intravenous bisphosphonates for patients
with malignancies in particular [91]. Among malignancies
the vast majority of ONJ cases are seen in myeloma and
breast cancer. The underlying cause of this selectivity is still
unknown. Cases also have been described in patients
receiving bisphosphonates for osteoporosis, but are much
rarer. Several large scale studies have estimated the risk in
osteoporosis to e between 1/10,000 and 1/100,000 [92, 93].
Atypical femoral fractures have also been reported in
several small case series and are mostly transverse fractures
of the femoral shaft in patients on long term treatment with
alendronate. The fracture event is usually preceded by
longstanding pain in the affected hip and most fractures
happen without fall-related trauma. Bilateral fractures may
occur, and on x-rays, signs of periosteal reaction and diffuse
or focal cortical thickening are usually seen [94]. Whether
direct causality between bisphosphonate use and these
fractures can ever be established is doubtful. In treatment
naive patients atypical fractures constitute 4% of all hip
fractures, and a large scale epidemiologic study from
Denmark could not demonstrate any correlation to long
term bisphosphonate use [95]. Currently, the general
consensus is that the benefit of significant reduction of all
hip fractures after bisphosphonate treatment far outweighs
the small risk of an atypical fracture, but strategies are
being developed in order to identify individuals at risk.
Alendronate was the first amino-bisphosphonate approved
by the US Food and Drug Administration for the treatment
and prevention of osteoporosis. The registration was based on
daily dosing of 10 mg/day. The Fracture Intervention Trial
(FIT) enrolled 2,027 older women with at least one prior
vertebral fracture and low femoral neck BMD. In this group
alendronate induced significant 47% and 51% reductions in
morphometric vertebral and hip fractures, respectively [58]. In
FIT subjects without prevalent vertebral fractures, alendro-
nate 10 mg decreased radiographic vertebral fractures by
44% [8]. A multinational study of alendronate similarly
identified a 47% risk reduction for nonvertebral fractures in
women with low bone mass [96]. A long-term extension to
the FIT study (FLEX) demonstrated the long term safety over
a period of 10 years. With the exception of clinical vertebral
fractures, fracture risk reduction at other skeletal sites was
statistically indistinguishable in those receiving 5 years on
followed by 5 years off of alendronate versus a full 10 years
of therapy [88]. Later, however, once-weekly preparation of
alendronate (70 mg) has greatly exceeded daily administra-
tion based on improved ease of use, and tolerability that is
equivalent to or better than daily therapy [97].
The decision about whether to stop therapy with
bisphosphonate after a finite period of time is subject to
debate. Further analysis of the FLEX data revealed that
women with a femoral neck BMD T score of −2.5 or below
at the 5-year mark had a higher risk of subsequent fractures
after discontinuation [98], so some centers have adopted
strategies where bisphosphonate treatment is discontinued,
only in patients where t-score is>−2,5.
Risedronate is a pyridinyl amino-bisphosphonate that
increases bone mass and prevents fractures [99]. In two
studies one US [59] and one multinational [100] VERT
(Vertebral Efficacy with Risedronate Therapy) studies,
1,226 and 2,458 postmenopausal women with at least one
prior vertebral fracture were were enrolled and randomized
to treatment with 5 mg of risedronate or Ca + D alone.
Women receiving risedronate exhibited 41–49% reduction
in vertebral fractures and 33–39% reduction in nonvertebral
fractures. The drug was also tested In the Hip Intervention
Program study, where risedronate 5 mg significantly
reduced hip fractures among women with confirmed low
bone mass but not among those selected primarily on the
basis of fall risks without documented osteoporosis [101].
Ibrandronate either orally (daily or monthly) or intrave-
nously reduced markers of bone turnover, increased BMD
[102], and reduced fractures of the vertebrae by 52% [103].
In the pivotal fracture study no significant reduction of hip
fractures was seen, but post hoc analyses claimed significant
reductions in individuals with baseline BMD t-scores at or
below −3.0.
Zoledronic acid is administered as a yearly 5 mg
intravenous infusion and significantly reduced both verte-
bral (by 70%) hip (by 41%) and non-vertebral fractures (by
25%) in postmenopausal women with osteoporosis [5]. The
drug was also tested in women and men after surgical repair
of a hip fracture, and in this population a significant
reduction in subsequent clinical fractures along with a
reduction in mortality was seen [10]. As with other iv.
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Bisphosphonates the main side effects include a post-dose
response, characterized by fever, myalgia and arthralgia in
about 15–20% of patients. These symptoms are seen mainly
after administration of the first dose, but rarely with
subsequent dosing, and seem to be less pronounced in
patients previously treated with oral bisphosphonates. Due
to the higher Cmax achieved with iv bisphosphonates the
risk of renal impairment is increased over oral adminsitra-
tion. However, if a minimum infusion time of 15 min is
adhered to. and a baseline creatinine clearance of 35 ml/min
is used at cut off for institution of treatment, no increase in
renal side effects over placebo are seen [104].
1.4 Effects of bisphosphonates in osteopenia
The FIT II study studied 8,704 women with low fermoral neck
BMD, but no prevalent vertebral fractures, who were
randomized to alendronate (5–10 mg) or placebo for a period
of 4 years. The primary endpoint was reduction of all clinical
fractures (spine, hip, nonvertebral) [8]. 63% of women
exhibited t-scores in the osteopenic range (in this study t-
scores between −1,6 and −2,5): Alendronate did not
significantly reduce clinical fractures in women with baseline
t-scores in the osteopenic range, but induced significant
reduction (44%) of morphometric vertebral fractures. The
NNT to prevent 1 vertebral fracture ranged between 59 and
363 in the lower and higher osteopenic range, respectively
[8]. The FOSIT study evaluated the safety and effects on
bone mineral density (BMD) of alendronate 10 mg in
postmenopausal women with lumbar spine BMD t-score of
−2 or more. After 12 months the incidence of nonvertebral
fractures was reduced significantly by 47% [96].
1.4.1 Parathyroid hormone
Continuous excessive secretion of parathyroid hormone
(PTH) (e.g. primary hyperparathyroidism) causes bone
catabolism, characterized by cortical bone loss in
particular [105]. In contrast, exogenously administered
intermittent PTH leading to a peak of excess PTH for
about 3 h is anabolic due to stimulation of osteoblastic
bone formation and increased skeletal remodeling activity.
Daily administration of the approved dose of 20 ug of
PTH fragment [1–34] (teriparatide) increased BMD by an
average of 9.7% in human studies [61, 106, 107] and
significantly decreased the risk of vertebral (65% risk
reduction in those on 20 ug/day) and nonvertebral
fractures (35% with 20 ug/day) and increased BMD at
all sites investigated, except for the radial shaft [61].
Nonvertebral fragility fractures were reduced by 53%. The
initial decrease at this site, coincides with the maximal
increase in cortical porosity seen with the drug at 6 months
[108]. Teriparatide increases cancellous bone volume,
restores trabecular bone architecture and increases cortical
thickness. It also leads to periosteal new bone formation
and increases cross-sectional area, potentially increasing
cortical bone strength [109]. These are specific cortical
effects, which are not seen with anti-resorptive drugs, and
they may be responsible for the pronounced reduction of
non-vertebral fractures by up to 80% in patients treated for
more than 18 months in a post hoc analysis of clinical
fractures in the pivotal PTH trial [110].
Full length PTH [1–84] has also been tested as a
treatment modality for osteoporosis. The dose used was
100 ug/Day, which is equivalent to a PTH [1–34] dose of
40 ug. In a study on 2,532 postmenopausal women, PTH
[1–84] increased spine and hip BMD by 6,9 and 2,1%,
respectively, and reduced the risk for new or worsened
vertebral fractures by 40%. No reduction of nonvertebral
fractures was demonstrable [111].
PTH [1–34] and PTH [1–84] have both been associated
with nausea, and headache. PTH [1–34] 20 ug/day may
lead to asymptomatic mild hypercalcemia, a side effect
seen more frequently with PTH [1–84], where dose
reduction regimens had to be instituted in a significant
number of patients in order to avoid symptomatic
hypercalcemia [111]. Clinical trials of teriparatide were
terminated early by the finding of osteosarcoma in Fisher
rats [61], and similar effects were seen with PTH [1–84].
However after widespread use in humans no significant
increase in osteosarcoma cases beyond the background
rate has been detected. Due to this finding in the initial
trial and in repeated toxicology trials in rats, PTH is
recommended for treatment for a limited period of 24-
months.
There is an enhanced effect on bone mass when PTH is
sequentially followed by antiresorptives like alendronate [112]
or estrogen [113], most probably due to a reduction of the
remodeling space brought about by these agents. If some kind
of antiresorptive treatment is not given, bone mass will return
to baseline within 2 years after discontinuation of PTH, albeit
anti-fracture efficacy seems preserved [114]. Oral bisphosph-
onates started prior to or concurrently with PTH may attenuate
bone mass improvement and bone marker increases seen with
PTH alone. Iv. Bisphosphonates seem to be causing less
blunting of the BMD and marker response [115].
PTH is currently used most commonly in adults with
severe osteoporosis,—many of whom have had fractures
while on other antiosteoporotic agents or have had intolerance
to bisphosphonates, and will rarely have indications in
osteopenic patients.
1.4.2 Denosumab
The discovery of the receptor activator of the nuclear factor
kappa B ligand RANKL/RANK/osteoprotegerin (OPG) path-
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way regulating osteoclastic differentiation has defined new
targets for inhibition of osteoclastic bone resorption. Denuso-
mab, a specific recombinant humanized monoclonal antibody
against RANKL, is the most effective suppressor of bone
resorption yet developed. It reduces bone turnover by over 95%
[116]. Consequently the BMD increases seen are more
pronounced than with other antiresorptives. In the pivotal
FREEDOM (Fracture Reduction Evaluation of Denosumab in
Osteoporosis Every 6 Months) study of nearly 8,000 women
[21], denosumab reduced the risk of new radiographic
vertebral fracture by 68%, with a cumulative incidence of
2.3% in the Denosumab group versus 7.2% in the placebo
group. Denosumab significantly reduced the risk of hip and
nonvertebral fracture by 40% and 20%, respectively. In
clinical trials with Denosumab, overall adverse events were
similar to placebo. There was no increase in the risk of cancer,
infection, cardiovascular disease, delayed fracture healing, or
hypocalcemia. In the osteoporosis trials with Denosumab
there were no cases of osteonecrosis of the jaw. In the
oncology trials with Denosumab, however, the risk of ONJ
was found to be similar to that of Zoledronic acid [117].
1.4.3 Strontium ranelate
Daily intake of strontium ranelate has been shown to reduce
the risk of vertebral and nonvertebral fractures in postmeno-
pausal women with osteoporosis or a prevalent vertebral
fracture or both. The exact MOA of strontium ranelate is still
poorly defined, however, but the drug increases matrix
mineralization and reduce spine fractures by 38% after 3 years
[118, 119]. In the pivotal trial on nonvertebral fractures no
significant overall reduction of hip fracture was seen, but in a
high risk subgroup (women over 74 years old with low
BMD at the femoral neck), a significant reduction of 36%
was seen [119]. Other post hoc analyses have demonstrated
efficacy in women with osteopenia and women older than
80 years [120].
2 Summary
An ever increasing array of effective treatments is at our
disposal, to protect patients with osteopenia against fractures.
While there is general consensus on treating osteopenic
individuals with prevalent low energy fractures, the treatment
of osteopenia without fracture is still debatable. However,
current evidence indicates that specific pharmacotherapy
should be instituted if an osteopenic patients has prevalent
fractures or suffers new fractures, be it clinical or asymptom-
atic. Moreover, a significant accumulation of several signifi-
cant risk factors, for example as indicated by the FRAX tool
may constitute an indication for pharmacotherapy. Patients
without such risk factors should be counselled on a “bone
friendly” lifestyle with nutritional modifications, regular
exercise, moderation in alcohol use and If possible smoking
cessation. In patients with low vitamin D levels, Ca + D
supplementation may also be indicated (Fig. 3).
Amino-bisphosphonates, taken orally or intravenously,
remain the dominant treatment modalities for osteoporosis.
They reduce fracture risk in osteoporotic as well as
osteopenic individuals. Questions exist about the very-
long-term safety of these drugs, but the best data available
so far [88], suggest that 10 years with 90% suppression of
bone turnover is safe. Denosumab constitutes a future
alternative to bisphosphonates. In younger postmenopausal
women with osteopenia, estrogen or estrogen/progestin still
has a place as a short term (up to 5 years) treatment,
especially in women with menopausal symptoms. Similarly
SERMs should be considered in younger postmenopausal
women, especially those at increased risk of breast cancer.
In males with low testosterone levels, testosterone substi-
tution is indicated as it improves skeletal integrity. We still
need long term controlled studies on this treatment, but the
risk of prostate cancer does not seem to be as big as
previously anticipated. Teriparatide, would currently rarely
be considered in women or men with cheaper anabolics
available, however, initial therapy with anabolics to bring
osteopenic patients out of the risk zone followed by an
antiresorptive would probably be the ideal treatment.
Treatment algorithm for osteopenia
Osteopenia









Major fx. risk < 20%
Hip fx. risk < 3% 
FRAX
Major fx. risk > 20%
Hip fx. risk > 3%
Fig. 3 Treatment in osteopenia is stratified according to presence or
absence of fractures. If a low energy fracture is demonstrated, specific
osteoporosis treatment with a bone active drug is indicated. If no fracture
is present, the FRAX based fracture risk should be calculated. If either the
calculated 10 year. risk of hip fracture or major osteoporotic fracture are
higher than 3% and 20%, respectively, specific osteoporosis therapy is
considered cost-effective. If the calculated risks are lower, general advice
on a bone friendly lifestyle (good nutrition, regular exercise, smoking
cessation etc.), should be given, and if vitamin D levels are low, calcium
and vitamin D-supplementation should be instituted
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